Literature DB >> 29553329

Candida auris Infection Leading to Nosocomial Transmission, Israel, 2017.

Ana Belkin, Zeala Gazit, Nathan Keller, Ronen Ben-Ami, Anat Wieder-Finesod, Ana Novikov, Galia Rahav, Tal Brosh-Nissimov.   

Abstract

A patient transferred from South Africa to Israel acquired a Candida auris infection. Phylogenetic analysis showed resemblance of C. auris to isolates from South Africa but not Israel, suggesting travel-associated infection. C. auris infection occurred weeks later in another patient at the same hospital, suggesting prolonged environmental persistence.

Entities:  

Keywords:  Candida auris; Israel; South Africa; fungi; nosocomial infection; outbreak; phylogeography; travel

Mesh:

Substances:

Year:  2018        PMID: 29553329      PMCID: PMC5875262          DOI: 10.3201/eid2404.171715

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


Candida auris is a multidrug-resistant yeast that has emerged over the past 3 years to cause nosocomial outbreaks in multiple countries. C. auris can cause serious invasive infections, may spread between patients, and can survive for months on hospital room surfaces (). Whole-genome sequencing has determined the presence of country-specific clades, which differ from one another by thousands of single-nucleotide polymorphisms (). The mode of spread between countries remains unclear. We present a case of international C. auris transmission related to a medically repatriated patient. A previously healthy 25-year-old Israeli man (patient A) was admitted to a hospital in Johannesburg, South Africa, after a motor vehicle accident on July 24, 2016. He had severe limb injury and underwent open reduction and internal fixation on both femurs, complicated by fat emboli, acute respiratory distress syndrome requiring mechanical ventilation, and ventilator-associated pneumonia. He was empirically treated with broad-spectrum antimicrobial drugs and caspofungin. Three weeks after the accident, he was transferred to the intensive care unit (ICU) of Sheba Medical Center, Tel Hashomer, Israel. Ten days after his arrival, a deep surgical-site infection developed in his left thigh. We initiated debridement and broad-spectrum antimicrobial drugs. After cultures obtained during surgery grew extended-spectrum β-lactamase–producing Klebsiella pneumoniae and meropenem-resistant Pseudomonas aeruginosa, we initiated contact isolation. Two of 3 deep-wound cultures grew C. auris. Two days later, 1 blood culture grew C. parapsilosis. We administered amphotericin B and appropriate antibacterial drugs, discontinuing amphotericin B after 10 days due to increased creatinine. The surgical site healed, and the patient was transferred to a rehabilitation unit. Rectal and skin surveillance cultures obtained 4 weeks after the first isolation of Candida were negative for C. auris. Routine ICU environmental disinfection included daily bleach cleaning of surfaces and quaternary ammonium wipes of sensitive medical equipment. In January 2017, we isolated C. auris from a urine culture obtained through a catheter of a 70-year-old patient (patient B) who was admitted to the Sheba Medical Center ICU 6 weeks after the discharge of patient A. Patient B had not traveled abroad recently. Surveillance cultures (urine, axilla, perineum) of patients in the ICU at the time of C. auris isolation of either patient A or B were negative for C. auris. One environmental sample from the floor next to patient B’s bed in proximity to the urinary catheter bag was positive for C. auris. All other environmental samples were negative. We removed the urinary catheter without further antimicrobial therapy. Strict environmental cleaning was performed in the ICU. We performed drug susceptibility testing using broth microdilution in accordance with Clinical Laboratory Standards Institute methods (https://clsi.org/standards/products/microbiology/documents/m27/) and reported results with preliminary breakpoints as published by the US Centers for Disease Control and Prevention (). The study was approved by the Sheba Medical Center institutional review board. We identified isolates as C. auris by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (Bruker Daltonik, Bremen, Germany) and as C. parapsilosis by the Phoenix system (Becton Dickinson, Franklin Lakes, NJ, USA). Sequence alignment with C. auris type strain CBS10913T produced similarity scores of 98% for internal transcribed spacer and 100% for large subunit ribosomal DNA segments for all 4 strains. Internal transcribed spacer and large subunit sequences of isolates from both patients were 100% identical to strains for MRL293 and MRL208 from South Africa () and distinct from sequences of strains previously isolated in our hospital and in Tel Aviv (Figure) ().
Figure

Phylogenetic analysis of Candida auris strains from 2 patients in Israel. Tree was generated using the neighbor-joining method. Internal transcribed spacer sequences of C. auris strains were aligned with the C. auris type strain CBS5149T, strains previously isolated in Tel Aviv (TA002-TA005), and additional clinical strains available from GenBank. A indicates isolates from patient A, who was transferred from South Africa to Sheba Medical Center in Israel in late 2016. B indicates isolates from patient B, who was admitted to the same unit 6 weeks after the discharge of patient A, in January 2017; SHB-713 is an environmental sample from the floor near patient B’s bed. C indicates isolates from sputum and urine from 2 different patients infected with C. auris in Sheba Medical Centerl during 2017 (SHB-720–723). The percentages of replicate trees in which the associated taxa clustered together in the bootstrap test (500 replicates) are shown next to the branches. GenBank accession numbers are given in parentheses, and countries of origin are listed. C. lusitaniae JCM1814T and Schizosaccharomyces pombe ATCC38366 were used as outgroups. Scale bar indicates nucleotide substitutions per site.

Phylogenetic analysis of Candida auris strains from 2 patients in Israel. Tree was generated using the neighbor-joining method. Internal transcribed spacer sequences of C. auris strains were aligned with the C. auris type strain CBS5149T, strains previously isolated in Tel Aviv (TA002-TA005), and additional clinical strains available from GenBank. A indicates isolates from patient A, who was transferred from South Africa to Sheba Medical Center in Israel in late 2016. B indicates isolates from patient B, who was admitted to the same unit 6 weeks after the discharge of patient A, in January 2017; SHB-713 is an environmental sample from the floor near patient B’s bed. C indicates isolates from sputum and urine from 2 different patients infected with C. auris in Sheba Medical Centerl during 2017 (SHB-720–723). The percentages of replicate trees in which the associated taxa clustered together in the bootstrap test (500 replicates) are shown next to the branches. GenBank accession numbers are given in parentheses, and countries of origin are listed. C. lusitaniae JCM1814T and Schizosaccharomyces pombe ATCC38366 were used as outgroups. Scale bar indicates nucleotide substitutions per site. C. auris isolates from patients A and B were resistant to fluconazole and susceptible to anidulafungin and had high MICs to voriconazole (>8 μg/mL). One isolate was resistant to amphotericin B (MIC 2 μg/mL) (), although a recent study suggested a higher epidemiologic cutoff that defines the isolate as susceptible (). Nosocomial outbreaks associated with C. auris were reported from several countries and continents including India, South Africa, Venezuela, Pakistan, and the United States (,,). Sporadic cases were reported from Israel (). Echinocandin exposure, which preceded C. auris infection in patient A, was also reported in South Africa (). Environmental contamination appears to be a common mode of C. auris spread within medical facilities (); it is the suspected cause for the 2 cases reported here, despite the time between them. The use of quaternary ammonium compounds, which are less effective than bleach, for disinfecting equipment might contribute to persistence of Candida (). International travel is an increasingly recognized risk factor for infection with drug-resistant pathogens. Our investigation underscores the potential role of international travel and especially the transportation of patients between countries as a mode of C. auris dissemination. The wide genetic gap between country-specific clades allows the use of ribosomal DNA typing as a tool for identifying the geographic origin of specific isolates (,). A similar approach was used to demonstrate multiple transmission events into the United Kingdom ().
  8 in total

1.  Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses.

Authors:  Shawn R Lockhart; Kizee A Etienne; Snigdha Vallabhaneni; Joveria Farooqi; Anuradha Chowdhary; Nelesh P Govender; Arnaldo Lopes Colombo; Belinda Calvo; Christina A Cuomo; Christopher A Desjardins; Elizabeth L Berkow; Mariana Castanheira; Rindidzani E Magobo; Kauser Jabeen; Rana J Asghar; Jacques F Meis; Brendan Jackson; Tom Chiller; Anastasia P Litvintseva
Journal:  Clin Infect Dis       Date:  2016-10-20       Impact factor: 9.079

2.  Investigation of the First Seven Reported Cases of Candida auris, a Globally Emerging Invasive, Multidrug-Resistant Fungus - United States, May 2013-August 2016.

Authors:  Snigdha Vallabhaneni; Alex Kallen; Sharon Tsay; Nancy Chow; Rory Welsh; Janna Kerins; Sarah K Kemble; Massimo Pacilli; Stephanie R Black; Emily Landon; Jessica Ridgway; Tara N Palmore; Adrian Zelzany; Eleanor H Adams; Monica Quinn; Sudha Chaturvedi; Jane Greenko; Rafael Fernandez; Karen Southwick; E Yoko Furuya; David P Calfee; Camille Hamula; Gopi Patel; Patricia Barrett; Patricia Lafaro; Elizabeth L Berkow; Heather Moulton-Meissner; Judith Noble-Wang; Ryan P Fagan; Brendan R Jackson; Shawn R Lockhart; Anastasia P Litvintseva; Tom M Chiller
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2016-11-11       Impact factor: 17.586

3.  Effectiveness of Disinfectants Against Candida auris and Other Candida Species.

Authors:  Jennifer L Cadnum; Aaron A Shaikh; Christina T Piedrahita; Thriveen Sankar; Annette L Jencson; Emily L Larkin; Mahmoud A Ghannoum; Curtis J Donskey
Journal:  Infect Control Hosp Epidemiol       Date:  2017-08-10       Impact factor: 3.254

4.  Isolates of the emerging pathogen Candida auris present in the UK have several geographic origins.

Authors:  Andrew M Borman; Adrien Szekely; Elizabeth M Johnson
Journal:  Med Mycol       Date:  2017-07-01       Impact factor: 4.076

5.  Comparison of EUCAST and CLSI Reference Microdilution MICs of Eight Antifungal Compounds for Candida auris and Associated Tentative Epidemiological Cutoff Values.

Authors:  M C Arendrup; Anupam Prakash; Joseph Meletiadis; Cheshta Sharma; Anuradha Chowdhary
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

6.  Notes from the Field: Ongoing Transmission of Candida auris in Health Care Facilities - United States, June 2016-May 2017.

Authors:  Sharon Tsay; Rory M Welsh; Eleanor H Adams; Nancy A Chow; Lalitha Gade; Elizabeth L Berkow; Eugenie Poirot; Emily Lutterloh; Monica Quinn; Sudha Chaturvedi; Janna Kerins; Stephanie R Black; Sarah K Kemble; Patricia M Barrett; Kerri Barton; D J Shannon; Kristy Bradley; Shawn R Lockhart; Anastasia P Litvintseva; Heather Moulton-Meissner; Alicia Shugart; Alex Kallen; Snigdha Vallabhaneni; Tom M Chiller; Brendan R Jackson
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2017-05-19       Impact factor: 17.586

7.  Multidrug-Resistant Candida haemulonii and C. auris, Tel Aviv, Israel.

Authors:  Ronen Ben-Ami; Judith Berman; Ana Novikov; Edna Bash; Yael Shachor-Meyouhas; Shiri Zakin; Yasmin Maor; Jalal Tarabia; Vered Schechner; Amos Adler; Talya Finn
Journal:  Emerg Infect Dis       Date:  2017-02       Impact factor: 6.883

8.  Candida auris-associated candidemia, South Africa.

Authors:  Rindidzani E Magobo; Craig Corcoran; Sharona Seetharam; Nelesh P Govender
Journal:  Emerg Infect Dis       Date:  2014-07       Impact factor: 6.883

  8 in total
  13 in total

1.  Invasive Candida auris infections in Kuwait hospitals: epidemiology, antifungal treatment and outcome.

Authors:  Ziauddin Khan; Suhail Ahmad; Khalifa Benwan; Prashant Purohit; Inaam Al-Obaid; Ritu Bafna; Maha Emara; Eiman Mokaddas; Aneesa Ahmed Abdullah; Khaled Al-Obaid; Leena Joseph
Journal:  Infection       Date:  2018-06-14       Impact factor: 3.553

Review 2.  Epidemiology, clinical characteristics, resistance, and treatment of infections by Candida auris.

Authors:  Andrea Cortegiani; Giovanni Misseri; Teresa Fasciana; Anna Giammanco; Antonino Giarratano; Anuradha Chowdhary
Journal:  J Intensive Care       Date:  2018-10-29

Review 3.  Emerging Fungal Infections: New Patients, New Patterns, and New Pathogens.

Authors:  Daniel Z P Friedman; Ilan S Schwartz
Journal:  J Fungi (Basel)       Date:  2019-07-20

Review 4.  Identification of Drug Resistant Candida auris.

Authors:  Milena Kordalewska; David S Perlin
Journal:  Front Microbiol       Date:  2019-08-20       Impact factor: 5.640

5.  Tracing the Evolutionary History and Global Expansion of Candida auris Using Population Genomic Analyses.

Authors:  Nancy A Chow; José F Muñoz; Anastasia P Litvintseva; Christina A Cuomo; Lalitha Gade; Elizabeth L Berkow; Xiao Li; Rory M Welsh; Kaitlin Forsberg; Shawn R Lockhart; Rodney Adam; Alexandre Alanio; Ana Alastruey-Izquierdo; Sahar Althawadi; Ana Belén Araúz; Ronen Ben-Ami; Amrita Bharat; Belinda Calvo; Marie Desnos-Ollivier; Patricia Escandón; Dianne Gardam; Revathi Gunturu; Christopher H Heath; Oliver Kurzai; Ronny Martin
Journal:  mBio       Date:  2020-04-28       Impact factor: 7.867

Review 6.  Review on Antifungal Resistance Mechanisms in the Emerging Pathogen Candida auris.

Authors:  Farid Chaabane; Artan Graf; Léonard Jequier; Alix T Coste
Journal:  Front Microbiol       Date:  2019-11-29       Impact factor: 5.640

7.  Prevalence and Therapeutic Challenges of Fungal Drug Resistance: Role for Plants in Drug Discovery.

Authors:  Lewis Marquez; Cassandra L Quave
Journal:  Antibiotics (Basel)       Date:  2020-03-31

8.  Candida auris in South Africa, 2012-2016.

Authors:  Nelesh P Govender; Rindidzani E Magobo; Ruth Mpembe; Mabatho Mhlanga; Phelly Matlapeng; Craig Corcoran; Chetna Govind; Warren Lowman; Marthinus Senekal; Juno Thomas
Journal:  Emerg Infect Dis       Date:  2018-11       Impact factor: 6.883

9.  Epidemiologic Shift in Candidemia Driven by Candida auris, South Africa, 2016-20171.

Authors:  Erika van Schalkwyk; Ruth S Mpembe; Juno Thomas; Liliwe Shuping; Husna Ismail; Warren Lowman; Alan S Karstaedt; Vindana Chibabhai; Jeannette Wadula; Theunis Avenant; Angeliki Messina; Chetna N Govind; Krishnee Moodley; Halima Dawood; Praksha Ramjathan; Nelesh P Govender
Journal:  Emerg Infect Dis       Date:  2019-09       Impact factor: 6.883

10.  Is the superbug fungus really so scary? A systematic review and meta-analysis of global epidemiology and mortality of Candida auris.

Authors:  Jingjing Chen; Sufei Tian; Xiaoxu Han; Yunzhuo Chu; Qihui Wang; Baosen Zhou; Hong Shang
Journal:  BMC Infect Dis       Date:  2020-11-11       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.